side view of scientist looking into microscope in bright research lab

Life Sciences & Healthcare


As a participant in the lifesciences industry, you know that discovery and innovation are key to finding lasting health solutions. Yet due to the highly regulated nature of the industry, you - a corporate, investor or start-up - must overcome complex administrative, compliance and liability hurdles before your products and services can come to market. With over 150 international specialists across CMS and the support of the Lifesciences Asia-Pacific Network (LAN), we understand the scientific and commercial as well as the legal imperatives affecting your business.

Our experts, many of whom have worked in-house in your sector, have developed a shared capability in the areas of pharmaceuticals, biotechnology, medical devices and diagnostics. With active memberships in the major industry associations such as the ABPI, ABHI, BIVDA, PAGB, EUCOMED and EFPIA, we help shape the legal frameworks impacting the lifesciences sector. We regularly advise our clients on their day to day operational needs such as support with public sector procurement, patent prosecution and enforcement, commercial agreements, tax and transfer pricing, and regulatory advice. Equally, when you need lifesciences specialist advice for strategic agreements, planning a corporate transaction or embarking on litigation (whether product liability or otherwise), we have a team that is well versed in the industry issues to help you.

Read more Read less
Ex­pect­a­tion of a Faster Growth of Health Food in Near...
China In­sight - Lifes­ci­ences
New GCP of Med­ic­al Devices
China In­sight - Lifes­ci­ences
China En­cour­ages In­nov­at­ive Drug by Modi­fy­ing Its Drug...
China In­sight - Lifes­ci­ences


Show only
Nicolas Zhu
Over­seas In­spec­tion of Drugs and Med­ic­al Devices
China In­sight - Life Sci­ences
China Life Sci­ences and Health­care monthly up­date - March 2019
State Coun­cil will de­ploy fur­ther pref­er­en­tial policies for anti-can­cer drugs over 2019, 19 Feb­ru­ary 2019 In an ex­ec­ut­ive meet­ing on 19 Feb­ru­ary 2019, the State Coun­cil of the People's Re­pub­lic of China ("State Coun­cil") an­nounced that six pref­er­en­tial policies.
Dec 2018
CMS Life Sci­ences & Health­care Sec­tor Group: An over­view...
China Life Sci­ences & Health­care Monthly Up­date - Decem­ber 2018
SAMS Con­sulta­tion on Vac­cine Man­age­ment Law, 11 Novem­ber The State Ad­min­is­tra­tion for Mar­ket Su­per­vi­sion (“SAMS”) of the People's Re­pub­lic of China (“PRC”) re­leased the PRC Vac­cine Man­age­ment Law (Draft for com­ment) (“Draft”) on 11 Novem­ber 2018.
Nicolas Zhu
Ex­ten­sion of Pi­lot Peri­od of MAH Hold­er Sys­tem
China In­sight - Life Sci­ences
China launches an in­ter­pro­vin­cial medi­cine pro­cure­ment re­gime
Fol­low­ing the fifth meet­ing of the Cent­ral Com­pre­hens­ively Deep­en­ing Re­forms Com­mis­sion of the Com­mun­ist Party of China, the Joint Pro­cure­ment Of­fice of the People’s Re­pub­lic of China (“JPO”) re­cently re­leased the Medi­cine Cent­ral­ised Pro­cure­ment Doc­u­ment (“Doc­u­ment”).
Life Sci­ences & Health­care: China de­vel­op­ments 2017...
Ex­ten­sion of pi­lot peri­od of MAH Hold­er Sys­tem
Fol­low­ing the pro­mul­ga­tion of the De­cision of the Stand­ing Com­mit­tee of the Na­tion­al People’s Con­gress on Au­thor­iz­ing the State Coun­cil to Carry out the Pi­lot Drug Mar­ket­ing Au­thor­iz­a­tion Hold­er Sys­tem in Cer­tain Re­gions and Rel­ev­ant Is­sues on Novem­ber 4, 2015.
Up­com­ing CF­DA In­spec­tion on Class I and Class II Med­ic­al...
China In­sight - Life Sci­ences
China Life Sci­ences & Health­care Monthly Up­date – Septem­ber 2018
NHC guidelines on the clin­ic­al ap­plic­a­tion of new anti-tu­mour drugs, 21 Septem­ber The Na­tion­al Health Com­mis­sion (“NHC”) of the People’s Re­pub­lic of China (“PRC”) re­leased the Guidelines on the Clin­ic­al Ap­plic­a­tion of New Anti-tu­mour Drugs (“Guidelines”) on.
New Cir­cu­lar Fur­ther En­han­cing the De­vel­op­ment of the...
China In­sight - Life Sci­ences
China Life Sci­ences & Health­care Monthly Up­date – Septem­ber 2018
Vac­cine scan­dal in China, 16 Au­gust The com­mun­ist party’s most power­ful body, Polit­buro Stand­ing Com­mit­tee of the Com­mun­ist Party of China, de­cided to sack 6 top of­ficers after the vac­cine scan­dal, in­clud­ing the former head of China Na­tion­al Drug Ad­min­is­tra­tion.